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Abstract
Background: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III
trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line
treatment compared with gemcitabine alone.
Methods: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for
compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and
gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we
included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m2 Nab-P and
1 g/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67
(range 41–77) years, and 11 patients were aged ≥70 years.
Results: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine
patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %)
patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy.
Median carbohydrate antigen 19–9 level was 469 U/l (range 17.4–61546 U/l) and 29 patients (70.7 %) had referred
pain at the time of diagnosis. Patients received a median six cycles (range 1–14) of treatment. Overall response rate
was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966–8.034), and
median overall survival was 10 months (95 % CI 7.864–12.136). Treatment was well tolerated. No grade 4 toxicity
was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %),
anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %).
Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 %
according to the Karnofsky scale.
Conclusions: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall
response rate, progression-free survival and overall survival, with a good safety profile.
Keywords: Metastatic pancreatic cancer, Combination chemotherapy, Nab-paclitaxel, Gemcitabine
(Continued on next page)
* Correspondence: ferdinando.devita@unina2.it
1Division of Medical Oncology, Department of Internal and Experimental
Medicine “F. Magrassi”, Second University of Naples - School of Medicine, c/o
II Policlinico, Via Pansini, 5, 80131 Naples, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
De Vita et al. BMC Cancer  (2016) 16:709 
DOI 10.1186/s12885-016-2671-9
(Continued from previous page)
Abbreviations: ALT, Alanine amino transferase; AST, Aspartate amino transferase; CBR, Clinical benefit rate;
CI, Confidence interval; CR, Complete response; DCR, Disease control rate; G, Gemcitabine; HR, Hazard ratio;
KPS, Karnofsky performance status; Nab-P, Nab-Paclitaxel; NLR, Neutrophil to lymphocyte ratio; ORR, Objective
response rate; OS, Overall survival; PDAC, Pancreatic ductal adenocarcinoma; PFS, Progression free survival;
PR, Partial responses
Background
Pancreatic adenocarcinoma represents ~3 % of newly di-
agnosed cancers annually worldwide [1]. It is an aggres-
sive disease and despite the efforts of the past few
decades, the 5-year overall survival (OS) rate remains
poor and does not exceed 5 % [2]. Most patients are di-
agnosed with locally advanced or metastatic disease, and
their only treatment approach is palliative chemotherapy
[3]. Since 1997, single-agent gemcitabine has been
regarded as first-line standard of care in metastatic dis-
ease. However, subsequently, most gemcitabine-based
chemotherapy regimens have not been able to improve
OS significantly when compared with alone [4–10]. Only
recently, the four-drug regimen FOLFIRINOX (oxalipla-
tin, irinotecan, fluorouracil and leucovorin) has been
shown to improve the objective response rate (ORR),
progression-free survival (PFS) and OS compared with
single agent gemcitabine, albeit with a significant toxicity
profile [11]. In preclinical studies, albumin-bound pacli-
taxel particles (Nab-P) have been shown to exert anti-
tumor activity as a single agent and synergistic activity
in combination with gemcitabine in murine models of
pancreatic cancer [12, 13]. On the basis of preclinical
evidence, a phase I–II clinical trial of Nab-P combined
with gemcitabine showed promising results in previously
untreated patients with metastatic pancreatic adenocar-
cinoma, with a median survival of 12.2 months and
manageable safety profile [14]. In a subsequent random-
ized phase III trial involving 861 patients, this combin-
ation was demonstrated to improve OS, PFS and ORR
significantly over gemcitabine alone, thus establishing
the combination of Nab-P and gemcitabine as standard
first-line treatment for metastatic pancreatic cancer [15].
However, based on enrollment criteria, the population of
the above trial might have not fully mirrored real-life
clinical practice. Therefore, we carried out a retrospect-
ive analysis to evaluate efficacy and safety profile of this




From January 2012 to May 2014, patients with metastatic
pancreatic ductal adenocarcinoma (PDAC), receiving first-
line treatment with combination of Nab-P and gemcitabine,
were considered eligible for our retrospective analysis.
Written informed consent was obtained from each patient
before starting treatment in accordance with the Declar-
ation of Helsinky. The ethics committee of Second Univer-
sity of Naples approved the use of Nab-P plus gemcitabine
for compassionate use, on the evidence of good results
obtaining in phase I/II trial [14] and the use of date for our
retrospective analysis. Inclusion criteria were clinicopatho-
logically confirmed PDAC, age ≥18 years, Karnofsky per-
formance status (KPS) ≥60 %, adequate hematological
function (neutrophil count ≥1500/mm3, platelet count
≥100,000/mm3, and hemoglobin ≥ 9 g/dl), adequate hepatic
function [total bilirubin <1.5 times the upper limit of nor-
mal range (ULN), aspartate aminotransferase (AST) and
alanine amino transferase (ALT) ≤2.5 ×ULN or AST and
ALT ≤5.0 ×ULN in case of liver metastases], and adequate
renal function. Patients with prior adjuvant gemcitabine
treatment were included if treatment was completed at
least 6 months before. Data were censored on May 2014.
All patients treated with at least one cycle of Nab-P + gem-
citabine were included for analysis. The characteristics of
the series are summarized in Table 1.
Treatment schedule
Nab-P, 125 mg/m2, followed by 1 g/m2 gemcitabine, was
administered intravenously on days 1, 8 and 15 every
4 weeks until disease progression or evidence of unaccept-
able toxicity. Antiemetic prophylaxis with 5-HT3 antago-
nists plus dexamethasone was used in all patients.
Recombinant human granulocyte colony-stimulating fac-
tor and erythropoietin were administered as needed. Dose
reductions were applied in cases of grade 3/4 toxicity.
Assessments
Tumor response evaluation was performed every
12 weeks by means of spiral computed tomography. Re-
sponse Evaluation Criteria In Solid Tumors (RECIST)
1.1 were used [16]. Blood tests were performed at base-
line and then at each cycle, while measurement of the
carbohydrate antigen (CA)19-9 serum level was per-
formed at baseline and every 12 weeks. Activity was
evaluated in terms of ORR [defined as complete re-
sponse (CR) + partial response (PR)], and disease control
rate (defined as CR + PR + stable disease). Six-month
clinical benefit rate (CBR) was defined as improvement
of at least one of three parameters among KPS, weight
loss, and pain, without worsening in any others, in
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association with sustained DCR (disease control rate) for
at least 6 months. Efficacy was evaluated in terms of OS
and PFS. The former was defined as the interval between
the start of Nab-P and gemcitabine first-line therapy to
death or last follow-up visit. The latter was defined as
the interval between the start of Nab-P and gemcitabine
therapy to clinical progression or death or last follow-up
visit if disease did not progress. Safety was monitored by
investigators and reported in clinical charts according to
Common Toxicity Criteria for Adverse Events (CTCAE)
version 4.0. Variables assessed for prognostic correla-
tions included age ≥70 years, sex, KPS, primary tumor
site, baseline CA19-9 level ≥59 × ULN, presence of liver
metastases, multiple metastatic involvement, 12-week
decrease of CA19-9 level ≥50 % from baseline, basal bili-
rubin level, neutrophil to lymphocyte ratio (NLR), calcu-
lated as the absolute neutrophil count divided by the
absolute lymphocyte count measured in × 103/ml, and
biliary stent implantation.
Statistical analysis
Survival distribution was estimated by the Kaplan–Meier
method with 95 % confidence interval (CI) [17]. Differ-
ences in survival according to clinical parameters or
treatment were evaluated by the log-rank test and de-
scribed by the Kaplan–Meier method. For the final ana-
lysis, the survival status of all patients was updated
within 2 months before the data cutoff of May 2014.
Cox proportional-hazards model was applied to multi-
variate survival analysis. All the significant variables in
the univariate model were used to build the multivariate
model of survival. SPSS version 20.0 (Chicago, IL, USA)
was used for statistical analysis. Values of p ≤ 0.05 indi-
cated statistical significance.
Results
From January 2012 to May 2014, we retrospectively
reviewed the clinical records of 41 patients with PDAC.
Activity
The patients received a median of six cycles (range 1–
14) of treatment. Two CRs and 13 PRs were observed
for an ORR of 36.6 %. Stable disease was recorded in 14
patients, yielding a global DCR of 70.7 %. Twenty-seven
patients reported cancer-related pain or disease-related
symptoms before starting treatment; 24 (58.5 %) of them
benefitted by at least one point of pain relief according
to Numeric Rating Scale or symptom improvement,
resulting in a 6-month CBR of 51.2 %. A 12-week de-
crease of CA19-9 levels ≥50 % from baseline was re-
corded in 17 patients (41.5 %) (Table 2). Pearson
correlation analysis confirmed a positive, linear, statisti-
cally significant correlation between CA19-9 decrease
≥50 % from baseline and tumor response (Pearson cor-
relation 0.581, Sig. two-tailed 0.0001).
Efficacy
At the time of data censoring, 27 patients had disease
progression or had died; median PFS was 6.7 months
(95 % CI 5.966–8.034) (Fig. 1). Multivariate analysis
showed NLR ≥5 as an independent, negative, prognostic
Table 1 Baseline patient characteristics
Characteristic Nab-Paclitaxel plus Gemcitabine
(range)
AGE (range) 67 (41–77)
> 70 11 (26,8 %)
SEX
M 18 (43,9 %)
F 23 (56,1 %)
PS (Karnofsky)
100 % 18 (43,9 %)
80–90 % 14 (34.1 %)
60–70 % 9 (21,9 %)
PANCREATIC PRIMARY LOCATION
HEAD 24 (58.5 %)
BODY/TAIL 17 (41.5 %)
SITE OF METASTASIS
Lung 10 (24,3 %)
Node 7 (17 %)
Liver 30 (73,1 %)
Peritoneum 5 (12,2 %)
Bone 1 (2,4 %)
No OF METASTATIC SITES
1 30 (73,1 %)
≥ 2 11 (26,9 %)
BILIARY STENT 9 (21.9 %)
MEDIAN CA19.9 469 U/I (17.4–61546)




Table 2 Overall response rate
RESPONSE RATE
RC 2 (4.8 %)
RP 13 (31.7 %)
ORR 15 (36.6 %)
SD 14 (34.2 %)
DCR 26 (70.7)
PD 12 (29.3)
CA19.9 > 50 % reduction 17 (41.5 %)
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indicator (hazard ratio 3.845; 95 % CI 1.611–9.180; p =
0.002). Conversely, 12-week CA 19–9 decrease ≥50 %
from baseline was demonstrated to be an independent,
positive, prognostic factor (hazard ratio 0.274; 95 % CI
0.09–0.689; p = 0.006). Median PFS of patients with NLR
<5 and NLR ≥5 was 8 and 3 months, respectively (p =
0.005) (Fig. 2). Median PFS was 4 months for patients
with CA 19–9 decrease <50 % and 9 months for those
with CA19-9 decrease ≥50 % (p = 0.007) (Fig. 3).
Survival analysis was based on 19 deaths (46 %).
Median OS was 10 months (95 % CI 7.864–12.136),
with a 12-month OS rate of 30.8 % (Fig. 4). Three
patients (7.3 %) were still alive at 24 months after
starting chemotherapy. OS was 12 and 7 months for
patients with NLR <5 and ≥5, respectively (p = 0.0001)
(Fig. 5). Furthermore, 12-week CA 19–9 decrease
≥50 % from baseline was significantly correlated with
better PFS (p = 0.006). NLR ≥5 was the only variable
Fig. 1 Progression free survival
Fig. 2 Progression free survival according to neutrophil to lymphocyte ratio (NLR)
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showing a significant correlation with OS on univari-
ate analysis (p = 0.002) (Tables 3 and 4).
Safety
Treatment was well tolerated, and most toxicity was
grade 1 or 2. No grade 4 events were recorded. Grade 3
toxicity comprised neutropenia in 10 patients (24.3 %),
thrombocytopenia in five (12 %), anemia in three
(7.3 %), diarrhea in four (9.7 %), nausea and vomiting in
two (4.9 %), and fatigue in six (14.6 %). None of the pa-
tients discontinued treatment because of unacceptable
toxicity; however, 20 % dose reduction of Nab-P alone,
gemcitabine alone, or both drugs was needed in three
(7.3 %), one (2.4 %), and two (4.9 %) patients, respect-
ively (Table 5). Questionnaires on quality of life, before
treatment and at each re-evaluation, were administered
to all patients, yielding a 6-month CBR of 51.2 %, with
77.8 % of patients reporting an improvement in KPS.
Discussion
Prospective, randomized, phase III trials provide the best
available evidence for comparison of different cancer
treatments, to be eventually used as new standards of care
in clinical practice. However, patients enrolled in clinical
trials do not always fully mirror the characteristics of a
real-life population. Thus, each novel oncological treat-
ment needs to be assessed in daily clinical practice. Ac-
cording to the results of the randomized phase III
MPACT trial, the addition of Nab-P to gemcitabine in pa-
tients with metastatic pancreatic cancer yielded significant
clinical improvements in all endpoints across all sub-
groups, compared with gemcitabine alone [12]. Despite
the limitations of a small series, we were able to confirm
efficacy of Nab-P and gemcitabine in a cohort of patients
observed in routine clinical practice. Specifically, we re-
corded a median OS of 10 months, median PFS of
6.7 months, and ORR of 26.7 %.
These data are even more significant when taking into
account that a higher proportion of patients in our study
was aged >70 years and had a KPS of 60–70 % compared
with the population of the pivotal study (MPACT trial).
Although pancreatic cancer mostly affects elderly people,
clinical trials often include disproportionately fewer eld-
erly patients than is commonly encountered in everyday
clinical practice; furthermore, older age commonly leads
to under-treatment in routine practice [18, 19]. This be-
havior is not justified by the results of retrospective
studies, which showed no differences in outcome be-
tween older patients treated with palliative chemother-
apy and younger patients enrolled in clinical trials [20].
In contrast, poor KPS is recognized as a major inde-
pendent prognostic factor for OS in all patients with
pancreatic cancer [21, 22]. In the MPACT trial, only
10 % of patients were older than 75 years and only 8 %
had a KPS of 60–70 % [12]. Conversely, 26.8 % of our
patients were older than 70 years, while 22 % had a KPS
of 60–70 %. In our study, median PFS and median OS
were higher than in the MPACT trial, although 22 % of
patients had KPS of 60–70 % and the long-term analysis
in the MPACT trial showed no survival benefit with
gemcitabine and Nab-P in this subgroup of patients [23].
A potential bias seen in our retrospective study could
be the timing of our assessment, namely, 12 weeks.
However we used this timing according to our clinical
practice. There is no standard second-line treatment fol-
lowing failure of first-line chemotherapy; however,
second-line treatment does provide a survival benefit
Fig. 3 PFS according to Ca 19.9 response
Fig. 4 OS
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when compared with best supportive care [24–26].
Sixty-one percent of our patients received second-line
treatment, mostly with capecitabine and oxaliplatin;
therefore, we cannot rule out the possibility that the OS
rate recorded in our study was affected by subsequent
chemotherapy. However, the availability of an effective
first-line regimen, Nab-P and gemcitabine, could allow
maintenance of a better KPS, thus increasing the chance
of exposing patients to subsequent treatment lines, with
consequent benefit in terms of OS.
Of note, the safety profile in our study was concordant
with that reported in the pivotal trial. The regimen was
well tolerated and no patient required treatment discon-
tinuation. Adverse events were generally grade 3 or lower
and no grade 4 hematological or non hematological tox-
icity was observed. Although peripheral neurotoxicity was
reported in 12.2 % of our patients, consistent with data re-
ported in the MPACT study, it was rapidly reversible in
most patients, with temporary discontinuation of Nab-P
and subsequent dose reduction.
Among the prognostic factors related to PFS and OS
evaluated in our study, CA19-9 levels and NLR >5 were
of particular value. A CA19-9 decrease from baseline of
>50 % turned out to be a positive independent
prognostic factor related to PFS. Specifically, median
PFS of patients with a decrease from baseline of <50 %
was 3 months, while patients with a decrease of >50 %
had a median PFS of 9 months. NLR >5 was shown to
correlate negatively with PFS. Patients with NLR <5 had
a median PFS of 8 months, whereas patients with NLR
>5 had a median PFS of 3 months. NLR ≥5 was the only
variable showing a significant correlation with OS on
univariate analysis. Therefore, in accordance with the re-
sults of the MPACT trial, our study confirmed both
serum levels of CA 19–9 and NLR as outcome predic-
tors in patients with metastatic pancreatic cancer. In
particular, NLR prognostic value points to the relevance
of systemic inflammatory response in affecting outcome
in patients with advanced pancreatic cancer [27, 28].
Table 3 Multivariate analysis PFS
MULTIVARIATE ANALYSIS (PFS)
HR 95 % CI p
KPS 2,18 0,8–5,9 0,125
CA19.9 RESPONSE 0,27 0,1–0,68 0,006
NLR≥ 5 3,84 1,6–9,2 0,002
BILIRUBIN 1,4 0,59–3,3 0,444
Table 4 Univariate analysis OS
UNIVARIATE ANALYSIS (OS)
HR 95 % CI p
AGE 0,78 0,32–1,89 0,6
SEX 0,63 0,28–1,41 0,3
TUMOR SITE 1,2 0,53–2,72 0,6
LIVER METASTASIS 1,61 0,67–3,8 0,3
MULTIPLE METASTASIS 0,9 0,35–2,3 0,8
KPS 1,9 0,58–6,2 0,3
BILIARY STENT 1,13 0,44–2,9 0,8
BILIRUBIN 1,8 0,8–4 0,1
CA19.9 BASELINE 1,75 0,62–4,9 0,3
CA19.9 DECREASE 0,59 0,25–1,37 0,2
NLR ≥ 5 4,3 1,7–10,8 0,002
Fig. 5 Overall survival according to neutrophil to lymphocyte ratio (NLR)
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Conclusions
After years in which the therapeutic options for metastatic
pancreatic cancer have been scarce, FOLFIRINOX and
Nab-P plus gemcitabine now represent two new options
for treatment of metastatic pancreatic adenocarcinoma. In
particular, our results confirm the activity, efficacy and tol-
erability of gemcitabine plus Nab-P as standard first-line
treatment in patients with metastatic pancreatic cancer.
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